Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF

Progress in Brain Research

Volumn 138, Issue , 2002, Pages 421-432

  McBride, Jodi L ^a   Kordower, Jeffrey H ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; CELL PROTECTION; CONFERENCE PAPER; DRUG INDUCED DISEASE; DYSTONIA; HERPES SIMPLEX VIRUS; HUMAN; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PALLIDOTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRAIN; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MODELS, ANIMAL; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT OUTCOME; VIRUSES;

EID: 0036458044     PISSN: 00796123     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0079-6123(02)38091-9     Document Type: Article

References (45)

1. Alexi, T., Borlongan, C.V., Faull, R.L.M., Williams, C.E., Clark, R.G., Gluckman, P.D. and Hughes, P.E. (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Progr. Neurobiol., 60: 409-470.
2. Apfel, S.C. (1997) Administration to the central nervous system. In: Clinical Applications of Neurotrophic Factors. Lippincott-Raven, Philadelphia, PA, pp. 185-199.
3. Arenas, E., Trupp, M., Akerud, P. and Ibanez, C.F. (1995) GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron, 15: 1465-1473.
4. Bensadoun, J.C., Deglon, N., Tseng, J.L., Ridet, J.L., Zurn, A.D. and Aebischer, P. (2000) Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's Disease using GDNF. Exp. Neurol., 164(1): 15-24.
5. Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.J., Mallet, J. and Horellou, P. (1997) Intrastriatal injection of an adenoviral vector expressing Glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's Disease. Proc. Natl. Acad. Sci. USA, 94: 8818-8823.
6. Bjorklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C. and Mandel, R.J. (2000) Towards a neuroprotective gene therapy for Parkinson's Disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res., 886(1-2): 82-98.
7. Borello, M.G., Alberti, L., Arighi, E., Bongarzone, I., Battistine, C., Bardelli, A., Pasini, B., Piutti, C., Rizzetti, M.G., Mondellini, P., Radice, M.T. and Pierotti, M.A. (1996) The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase C gamma. Mol. Cell Biol., 16(5): 2151-2163.
8. Broom, J.D., Wills, K.V., Lapchak, P.A., Ghetti, B., Camp, L.L. and Bayer, S.A. (1999) Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons from the lethal action of the weaver gene: A quantitative immunocytochemical study. Dev. Brain Res., 116(1): 1-7.
9. Buj-Bello, A., Buchman, V.L., Horton, A., Rosenthal, A. and Davies, A.M. (1995) GDNF is an age-specific survival factor for sensory and autonomic neurons. Neuron, 15: 821-828.
10. Carvey, P.M. (1998) Drug Action in the Central Nervous System. Oxford University Press, New York.
11. Choi-Lundberg, D.L., Lin, Q., Chang, Y.N., Chiang, Y.L., Hay, C.M., Mohajeri, H., Davidson, B.L. and Bohn, M.C. (1997) Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science, 275: 838-841.
12. Connor, B., Kozlowski, D.A., Schallert, T., Tillerson, J.L., Davidson, B.L. and Bohn, M.C. (1999) Differential effects of glial cell line-derived nerrotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther., 6(12): 1936-1951.
13. Deglon, N., Tseng, J.L., Bensadoun, J.C., Zurn, A.D., Arsenijevic, Y., Pereira de Almeida, L., Zuffery, R., Trono, D. and Aebischer, P. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther., 11(1): 179-190.
14. Gash, D.M., Zhang, Z., Cass, W.A., Ovadia, A., Simmerman, L., Martin, D., Russell, D., Collins, F., Hoffer, B.J. and Gerhardt, G.A. (1995) Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol., 363(3): 345-358.
15. Gash, D.M., Zhang, Z., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J. and Gerhardt, G.A. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature, 380: 252-255.
16. Henderson, C.E., Phillips, H.S., Pollock, R.A., Davies, A.M., Lemuelle, C., Armanini, M., Simpson, L.C., Moffet, B., Vandlen, R.A., Koliatsos, V.E. and Rosenthal, A. (1994) GDNF: A potent survival factor for motorneurons present in peripheral nerve and muscle. Science, 266: 1062-1064.
17. Hoffer, B.J., Hoffman, A., Bowenkamp, K., Huettl, P., Hudson, J., Martin, D., Lin, L.-F.H. and Gerhardt, G.A. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett., 182: 107-111.
18. Hudson, J., Granholm, A.C., Gerhardt, G.A., Henry, M.A., Hoffman, A., Biddle, P., Leela, N.S., Mackerlova, L., Lile, J.D. and Collins, F. et al. (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull., 36: 425-432.
19. Hughes, P.E., Alexi, T., Walton, M., Williams, C.E., Dragunow, M., Clark, R.G. and Gluckman, P.D. (1999) Activity and injury-dependent expression of inducible trophic factors, growth factors, and apoptosis-related genes within the central nervous system. Progr. Neurobiol., 57: 421-450.
20. Kastner, A., Hirsh, E.C., Agid, Y. and Javoy-Agid, F. (1993) Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brian Res., 606(2): 341-345.
21. Kirik, D., Rosenblad, C. and Bjorklund, A. (2000) Preservations of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci., 12(11): 3871-3882.
22. Kojima, H., Abiru, Y., Sakajira, K., Watabe, K., Ohishi, N., Takamori, M., Hatanaka, H. and Yagi, K. (1997) Adenovirus-mediated transduction with human Glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl, 1,2,3,6-tetrahydro-pyridine-induced dopamine depletion in striatum of mouse brain. Biochem. Biophys. Res. Commun., 238: 569-573.
23. Kordower, J.H., Palfi, S., Chen, E., Ma, S.Y., Sendera, T., Cochan, E.J., Mufson, E.J., Penn, R., Goetz, C.G. and Comella, C.D. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's Disease. Ann. Neurol., 46(3): 419-424.
24. Kordower, J.H., Bloch, J., Ma, S.Y., Chu, Y., Palfi, S., Roitberg, B.Z., Emborg, M.E., Hantraye, P., Deglon, N. and Aebischer, P. (2000a) Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol., 160(1): 1-16.
25. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N. and Aebischer, P. (2000b) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290(5492): 767-773.
26. Lang, A.E. and Lozano, A.M. (1998a) Parkinson's Disease: First of two parts. N. Engl. J. Med., 339: 1044-1053.
27. Lang, A.E. and Lozano, A.M. (1998b) Parkinson's Disease: Second of two parts. N. Engl. J. Med., 339: 1130-1143.
28. Lapchak, P.A., Miler, P.J., Collins, F. and Jiao, S. (1997) Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: Comparison of intraventricular and intranigral delivery. Neuroscience, 78: 61-72.
29. Levi-Montalcini, R. and Hamburger, V. (1953) A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo. J. Exp. Zool., 123: 233-287.
30. Lin, L.F., Doherty, D.H., Lile, J.D., Bektesh, S. and Collins, F. (1993) GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 260: 1130-1132.
31. Mandel, R.J., Spratt, S.K., Snyder, R.O. and Leff, S.E. (1997) Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA, 94(25): 14083-14088.
32. Mandel, R.J., Snyder, R.O. and Leff, S.E. (1999) Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's Disease. Exp. Neurol., 160(1): 205-214.
33. Martin, D., Miller, G., Rosendahl, M. and Russell, D.A. (1995) Potent inhibitory effects of Glial derived neurotrophic factor against kainic acid mediated seizures in the rat. Brain Res., 683: 172-178.
34. Mattson, M.P. (1998) Neuroprotective strategies based on targeting of postreceptor signaling events. In: Neuroprotective Signal Transduction. Humana Press, Totown, NJ, pp. 301-335.
35. Miyoshi, Y., Zhang, Z., Ovadia, A., Lapchak, P.A., Collins, F., Hilt, D., Lebel, C., Kryscio, R. and Gash, D.M. (1997) Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol., 42(2): 208-214.
36. Mount, H.T.J., Dean, D.O., Alberch, J., Dreyfus, C.F. and Black, I.B. (1995) Glial cell line-derived neurotrophic factor promotes the survival and morphologic differentiation of Purkinje cells. Proc. Natl. Acad. Sci. USA, 92: 9092-9096.
37. Naldini, L., Blomer, U., Gage, F.S., Trono, D. and Verma, I.M. (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA, 93(21): 11382-11388.
38. Rosenblad, C., Kirik, D. and Björklund, A. (2000) Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol., 161(2): 503-516.
39. Sautter, J., Tseng, J.L., Braguglia, D., Aebischer, P., Spenger, C., Seiler, R.W., Widmer, H.R. and Zurn, A.D. (1998) Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol., 149: 230-236.
40. Tomac, A., Lindqvist, E., Lin, L.-F.H., Ogren, S.O., Young, D., Hoffer, B.J. and Olson, L. (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature, 373: 335-339.
41. Trupp, M., Belluardo, N., Funakoshi, H. and Ibanez, C.F. (1997) Complementary and overlapping expression of Glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-α indicates multiple mechanisms of trophic actions in the adult rat CNS. J. Neurosci., 17(10): 3554-3567.
42. Tseng, J.L., Baetge, E.E., Zurn, A.D. and Aebischer, P. (1997) GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci., 17(1): 325-333.
43. Van Weering, D.H. and Bos, J.L. (1998) Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res., 154: 271-281.
44. Worby, C.A., Vega, Q.C., Zhao, Y., Chao, H.H., Seasholtz, A.Z. and Dixon, J.E. (1996) Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J. Biol. Chem., 271(39): 23619-23622.
45. Zhang, Z., Miyoshi, Y., Lapchak, P.A., Collins, F., Hilt, D., Lebel, C., Kryscio, R. and Gash, D.M. (1997) Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther., 282(3): 1396-1401.